EPIRUS BIOPHARMACEUTICALS INC COM
EPRS
EPRS was delisted on the 3rd of August, 2016.
21 hedge funds and large institutions have $21.3M invested in EPIRUS BIOPHARMACEUTICALS INC COM in 2014 Q3 according to their latest regulatory filings, with 21 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TGHSA
TPG Group Holdings (SBS) Advisors
Fort Worth,
Texas
|
+$19.2M |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
+$4.51M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$533K |
| 4 |
D.E. Shaw & Co
New York
|
+$260K |
| 5 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$221K |
Top Sellers
EPRS Hedge Fund Activity: Q3 2014 in Review
21 of the 3,455 institutional investors tracked by Wall St. Rank reported a position in EPIRUS BIOPHARMACEUTICALS INC COM (EPRS) for Q3 2014, worth a combined $21.3M.
Buyers outnumbered sellers: 21 funds opened new EPRS positions and 0 closed out — a net gain of 21 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was TPG Group Holdings (SBS) Advisors, opening a new position worth an estimated $19.2M.
- 21 institutional investors held EPIRUS BIOPHARMACEUTICALS INC COM (EPRS) as of Q3 2014, up from 0 in Q2 2014.
- Funds reported $21.3M of EPIRUS BIOPHARMACEUTICALS INC COM stock for Q3 2014.
- 21 funds opened new EPIRUS BIOPHARMACEUTICALS INC COM positions in Q3 2014 and 0 closed out, a net change of +21 holders.
- The largest EPIRUS BIOPHARMACEUTICALS INC COM buyer in Q3 2014 was TPG Group Holdings (SBS) Advisors, an estimated $19.2M added.
Based on aggregated 13F filings for Q3 2014.